Alector (ALEC) Competitors

Alector logo
$2.56 -0.02 (-0.58%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ALEC vs. ORIC, ODTX, RIGL, GLUE, and PHAR

Should you buy Alector stock or one of its competitors? Alector's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Odyssey Therapeutics (ODTX), Rigel Pharmaceuticals (RIGL), Monte Rosa Therapeutics (GLUE), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alector compare to Oric Pharmaceuticals?

Alector (NASDAQ:ALEC) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Oric Pharmaceuticals had 4 more articles in the media than Alector. MarketBeat recorded 12 mentions for Oric Pharmaceuticals and 8 mentions for Alector. Alector's average media sentiment score of 1.05 beat Oric Pharmaceuticals' score of 0.36 indicating that Alector is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oric Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alector has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Oric Pharmaceuticals has lower revenue, but higher earnings than Alector. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.05M17.93-$142.93M$0.357.24
Oric PharmaceuticalsN/AN/A-$129.47M-$1.35N/A

Alector has a net margin of 23.87% compared to Oric Pharmaceuticals' net margin of 0.00%. Alector's return on equity of 112.21% beat Oric Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alector23.87% 112.21% 18.37%
Oric Pharmaceuticals N/A -35.35%-33.39%

Alector presently has a consensus price target of $5.10, indicating a potential upside of 101.18%. Oric Pharmaceuticals has a consensus price target of $21.33, indicating a potential upside of 178.14%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43
Oric Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81

85.8% of Alector shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alector beats Oric Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Odyssey Therapeutics?

Alector (NASDAQ:ALEC) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Odyssey Therapeutics has lower revenue, but higher earnings than Alector. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.05M17.93-$142.93M$0.357.24
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Alector had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Alector and 2 mentions for Odyssey Therapeutics. Alector's average media sentiment score of 1.05 beat Odyssey Therapeutics' score of 1.04 indicating that Alector is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Odyssey Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alector currently has a consensus target price of $5.10, indicating a potential upside of 101.18%. Odyssey Therapeutics has a consensus target price of $34.67, indicating a potential upside of 77.69%. Given Alector's higher probable upside, equities analysts plainly believe Alector is more favorable than Odyssey Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Alector has a net margin of 23.87% compared to Odyssey Therapeutics' net margin of 0.00%. Alector's return on equity of 112.21% beat Odyssey Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alector23.87% 112.21% 18.37%
Odyssey Therapeutics N/A N/A N/A

Summary

Alector beats Odyssey Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Alector compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Rigel Pharmaceuticals has higher revenue and earnings than Alector. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$294.28M2.72$367.02M$15.512.74
Alector$21.05M17.93-$142.93M$0.357.24

Rigel Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 106.59% compared to Alector's net margin of 23.87%. Alector's return on equity of 112.21% beat Rigel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals106.59% 14.89% 11.99%
Alector 23.87%112.21%18.37%

Rigel Pharmaceuticals presently has a consensus price target of $66.75, suggesting a potential upside of 56.84%. Alector has a consensus price target of $5.10, suggesting a potential upside of 101.18%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

In the previous week, Alector had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 8 mentions for Alector and 5 mentions for Rigel Pharmaceuticals. Alector's average media sentiment score of 1.05 beat Rigel Pharmaceuticals' score of 0.10 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alector beats Rigel Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Monte Rosa Therapeutics has higher revenue and earnings than Alector. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M6.25-$38.63M-$1.40N/A
Alector$21.05M17.93-$142.93M$0.357.24

Monte Rosa Therapeutics presently has a consensus price target of $26.44, indicating a potential upside of 192.49%. Alector has a consensus price target of $5.10, indicating a potential upside of 101.18%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

Alector has a net margin of 23.87% compared to Monte Rosa Therapeutics' net margin of -186.24%. Alector's return on equity of 112.21% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-186.24% -30.14% -20.35%
Alector 23.87%112.21%18.37%

In the previous week, Alector had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Alector and 5 mentions for Monte Rosa Therapeutics. Alector's average media sentiment score of 1.05 beat Monte Rosa Therapeutics' score of 0.05 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alector beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Pharming Group presently has a consensus price target of $39.67, suggesting a potential upside of 223.02%. Alector has a consensus price target of $5.10, suggesting a potential upside of 101.18%. Given Pharming Group's stronger consensus rating and higher possible upside, research analysts plainly believe Pharming Group is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

In the previous week, Alector had 2 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Alector and 6 mentions for Pharming Group. Alector's average media sentiment score of 1.05 beat Pharming Group's score of 0.65 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alector has a net margin of 23.87% compared to Pharming Group's net margin of 6.23%. Alector's return on equity of 112.21% beat Pharming Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Pharming Group6.23% 8.70% 4.93%
Alector 23.87%112.21%18.37%

Pharming Group has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharming Group$376.13M2.31$2.85M$0.3238.38
Alector$21.05M17.93-$142.93M$0.357.24

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pharming Group has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Alector beats Pharming Group on 11 of the 16 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALEC vs. The Competition

MetricAlectorBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$379.50M$4.03B$7.73B$11.61B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio7.2823.9734.1629.83
Price / Sales18.0716.198.475.65
Price / CashN/A26.3721.9322.50
Price / Book3.284.064.373.65
Net Income-$142.93M-$22.82M$3.52B$392.18M
7 Day Performance0.99%-7.34%-5.48%-4.27%
1 Month Performance38.86%-6.15%-4.62%-6.75%
1 Year Performance106.05%-6.90%-1.57%-7.22%

Alector Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALEC
Alector
4.6959 of 5 stars
$2.56
-0.6%
$5.10
+99.6%
+107.3%$379.50M$21.05M7.28103
ORIC
Oric Pharmaceuticals
3.4868 of 5 stars
$8.82
+3.9%
$21.25
+140.9%
-38.6%$940.13MN/AN/A111
ODTX
Odyssey Therapeutics
2.38 of 5 stars
$19.23
+1.9%
$34.67
+80.3%
N/A$938.58MN/AN/A100
RIGL
Rigel Pharmaceuticals
4.3154 of 5 stars
$39.65
-13.3%
$65.50
+65.2%
+4.3%$934.91M$294.28M2.56174
GLUE
Monte Rosa Therapeutics
2.1485 of 5 stars
$10.57
+3.1%
$26.44
+150.2%
-36.2%$906.88M$123.67MN/A173

Related Companies and Tools


This page (NASDAQ:ALEC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners